Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $22.36 in the prior trading day, UroGen Pharma Ltd (NASDAQ: URGN) closed at $21.8, down -2.50%. In other words, the price has decreased by -$2.50 from its previous closing price. On the day, 0.44 million shares were traded. URGN stock price reached its highest trading level at $22.66 during the session, while it also had its lowest trading level at $21.78.
Ratios:
Our goal is to gain a better understanding of URGN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.79 and its Current Ratio is at 3.99.
Upgrades & Downgrades
In the most recent recommendation for this company, Piper Sandler on August 19, 2025, initiated with a Overweight rating and assigned the stock a target price of $36.
On June 16, 2025, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $50.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 19 ’25 when Schoenberg Mark sold 10,000 shares for $25.00 per share. The transaction valued at 250,000 led to the insider holds 139,025 shares of the business.
Schoenberg Mark bought 10,000 shares of URGN for $250,005 on Nov 19 ’25. On Oct 08 ’25, another insider, Degnan Chris, who serves as the Chief Financial Officer of the company, sold 2,203 shares for $16.85 each. As a result, the insider received 37,121 and left with 2,280 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, URGN now has a Market Capitalization of 1020433792 and an Enterprise Value of 1023340864. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.57. Its current Enterprise Value per Revenue stands at 10.603 whereas that against EBITDA is -7.806.
Stock Price History:
The Beta on a monthly basis for URGN is 1.28, which has changed by 0.9787611 over the last 52 weeks, in comparison to a change of 0.13613915 over the same period for the S&P500. Over the past 52 weeks, URGN has reached a high of $30.00, while it has fallen to a 52-week low of $3.42. The 50-Day Moving Average of the stock is 1.27%, while the 200-Day Moving Average is calculated to be 40.88%.
Shares Statistics:
The stock has traded on average 1.13M shares per day over the past 3-months and 826970 shares per day over the last 10 days, according to various share statistics. A total of 46.78M shares are outstanding, with a floating share count of 38.70M. Insiders hold about 17.52% of the company’s shares, while institutions hold 93.16% stake in the company. Shares short for URGN as of 1764288000 were 7950298 with a Short Ratio of 7.01, compared to 1761868800 on 11283704. Therefore, it implies a Short% of Shares Outstanding of 7950298 and a Short% of Float of 17.25.
Earnings Estimates
A comprehensive evaluation of UroGen Pharma Ltd (URGN) is underway, with the input of 7.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.51, with high estimates of -$0.36 and low estimates of -$0.63.
Analysts are recommending an EPS of between -$2.64 and -$3.4 for the fiscal current year, implying an average EPS of -$3.13. EPS for the following year is -$0.59, with 7.0 analysts recommending between $2.44 and -$1.7.
Revenue Estimates
8 analysts predict $41.45M in revenue for. The current quarter. It ranges from a high estimate of $51.57M to a low estimate of $32.86M. As of. The current estimate, UroGen Pharma Ltd’s year-ago sales were $24.57MFor the next quarter, 8 analysts are estimating revenue of $43.66M. There is a high estimate of $46.88M for the next quarter, whereas the lowest estimate is $40.1M.
A total of 8 analysts have provided revenue estimates for URGN’s current fiscal year. The highest revenue estimate was $123.52M, while the lowest revenue estimate was $104.81M, resulting in an average revenue estimate of $113.4M. In the same quarter a year ago, actual revenue was $90.4MBased on 8 analysts’ estimates, the company’s revenue will be $253.13M in the next fiscal year. The high estimate is $391.48M and the low estimate is $191.1M.
